12/1
10:19 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.
11/21
05:30 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/18
10:00 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Guggenheim from $28.00 to $43.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Guggenheim from $28.00 to $43.00. They now have a "buy" rating on the stock.
11/14
08:21 pm
cnta
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program [Yahoo! Finance]
Low
Report
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program [Yahoo! Finance]
11/13
10:48 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "overweight" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "overweight" rating on the stock.
11/11
08:40 pm
cnta
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11/11
04:00 pm
cnta
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
11/7
02:22 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $30.00. They now have an "overweight" rating on the stock.
Neutral
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $30.00. They now have an "overweight" rating on the stock.
11/7
08:00 am
cnta
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
High
Report
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
11/5
12:12 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
11/5
07:00 am
cnta
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Low
Report
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
10/28
06:01 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $35.00 price target on by analysts at Stephens.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $35.00 price target on by analysts at Stephens.
10/27
04:00 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
10/19
01:05 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by analysts at
Wal
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by analysts at
Wal
10/11
01:09 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
10/6
09:15 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $28.00 price target on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $28.00 price target on the stock.